ライフサイエンスコーパス: bone morphogenetic protein receptor

1 Ablation of bone morphogenetic protein receptor 1a (BMPR1A) in the O

2 Expression of bone morphogenetic protein receptor 1A (BMPR1A) is atten

3 developed from the vicinity of the gene for bone morphogenetic protein receptor 1A (BMPR1A), a serin

4 Reduced bone morphogenetic protein receptor 2 (BMPR2) expression

5 The effect of a mutation in the bone morphogenetic protein receptor 2 (BMPR2) gene on ri

6 Because decreased expression and function of bone morphogenetic protein receptor 2 (BMPR2) is observe

7 Bone morphogenetic protein receptor 2 (BMPR2) mutations

8 Bone morphogenetic protein receptor 2 (BMPR2) mutations

9 terized by endothelial dysfunction, impaired bone morphogenetic protein receptor 2 (BMPR2) signaling,

10 activin A receptor, type II-like 1 (ACVRL1), bone morphogenetic protein receptor 2 (BMPR2), and bone

11 inked to a mutation or reduced expression of bone morphogenetic protein receptor 2 (BMPR2).

12 g displays increased aromatase and decreased bone morphogenetic protein receptor 2 and Id1 expression

13 tations in the coding region of the gene for bone morphogenetic protein receptor 2 in patients with f

14 pproximately 20% concurrence of inactivating bone morphogenetic protein receptor 2 mutations and dela

15 Anastrozole treatment reversed the impaired bone morphogenetic protein receptor 2 pathway in females

16 expression may play a protective role in the bone morphogenetic protein receptor 2 unaffected carrier

17 itable PAH), most often through mutations of bone morphogenetic protein receptor 2, and idiopathic an

18 Dysfunctional bone morphogenetic protein receptor-2 (BMPR2) signaling

19 Bone morphogenetic protein receptor-2 (BMPR2)-heterozygo

20 made irrespective of the mutation status of bone morphogenetic protein receptor-2 in hypertensive pa

21 tically mediated as a result of mutations in bone morphogenetic protein receptor-2 or activin-like ki

22 rming growth factor-beta family receptor-II, bone morphogenetic protein receptor-2, and activin-like

23 with hyperactivating mutations of the type I bone morphogenetic protein receptor ACVR1 (Activin type

24 onent that is specifically phosphorylated by bone morphogenetic protein receptors and translocated in

25 /or cocaine due to severe down-modulation of bone morphogenetic protein receptor (BMPR) axis: the ant

26 Characterization of bone morphogenetic protein receptor (BMPR) expression du

27 ce suggests that serotonin, mutations in the bone morphogenetic protein receptor (BMPR) II gene, and

28 e mutations leading to reduced expression of bone morphogenetic protein receptor (BMPR) II, these mut

29 defects of angiopoetin-1 (ANG-1), TIE-2 and bone morphogenetic protein receptor (BMPR)-related signa

30 We have demonstrated that bone morphogenetic protein receptor (BMPR)-specific Smad

31 This phenotype resembled that of bone morphogenetic protein receptor (BMPR)1 and Gdf5-def

32 entify the brachydactyly gene as the type IB bone morphogenetic protein receptor, BmprIB (ALK6).

33 Here, we examine mice that lack functional bone morphogenetic protein receptors (BMPRs) in the reti

34 Large, round cells expressing bone morphogenetic protein receptors (BMPRs), which serv

35 zol-2-yl)benzamide] but not the inhibitor of bone morphogenetic protein receptor dorsomorphin, blocke

36 The Type I Bone morphogenetic protein receptor gene (Bmpr/Tfr-11/Br

37 HT), which is caused by mutations in TGFbeta/bone morphogenetic protein receptor genes, ENG, encoding

38 We demonstrate that signaling via the bone morphogenetic protein receptor IA (BMPR-IA) is requ

39 ent work, we showed that mRNA for the type I bone morphogenetic protein receptor IA (BMPR-IA) was pre

40 Loss-of-function mutations in bone morphogenetic protein receptor II (BMP-RII) are lin

41 Mutations in the bone morphogenetic protein receptor II (BMPR2) gene have

42 ry hypertension have defects in the gene for bone morphogenetic protein receptor II (BMPR2), a member

43 y members for mutations in the gene encoding bone morphogenetic protein receptor II (BMPR2), which ha

44 However, transforming growth factor beta and bone morphogenetic protein receptor II signaling, and hy

45 role of transforming growth factor beta and bone morphogenetic protein receptor II signaling, human

46 ifferential transforming growth factor beta, bone morphogenetic protein receptor II signaling, or car

47 owth factor (TGF)-beta superfamily receptor, bone morphogenetic protein receptor II, underlie heritab

48 tudies from our group have demonstrated that bone morphogenetic protein receptor-II (BMPR-II), expres

49 rphogenetic proteins through VE-cadherin and bone morphogenetic protein receptor-II/Smad5.

50 The daf-4 gene encodes a type II bone morphogenetic protein receptor in Caenorhabditis el

51 These might include integrin/bone morphogenetic protein receptor interactions or invo

52 t beta1-integrin directly interacts with the bone morphogenetic protein receptor subunits BMPR1a and

53 al-specific receptor for angiopoietin-1; and bone morphogenetic protein receptor type 1A (BMPR1A) and

54 Kip1, endothelial nitric oxide synthase, and bone morphogenetic protein receptor type 1a.

55 Expression of bone morphogenetic protein receptor type 2 (BMPR2) and i

56 erozygous mutations in the gene encoding the bone morphogenetic protein receptor type 2 (BMPR2) are t

57 Among them, the identification of bone morphogenetic protein receptor type 2 (BMPR2) as th

58 ith heritable PAH caused by mutations in the bone morphogenetic protein receptor type 2 (BMPR2) gene

59 l hypertension with germline mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene,

60 A variety of mutations in the bone morphogenetic protein receptor type 2 (BMPR2) have

61 Mutations in the bone morphogenetic protein receptor type 2 (BMPR2) have

62 In this study, we discovered that bone morphogenetic protein receptor type 2 (BMPR2) is es

63 he most common mutation leading to PAH is in bone morphogenetic protein receptor type 2 (BMPR2), orig

64 ing CD4 cells, and upregulation of pulmonary bone morphogenetic protein receptor type 2 (BMPR2)-expre

65 ized and are usually due to mutations in the bone morphogenetic protein receptor type 2 gene (BMPR2),

66 H (HPAH) is often caused by mutations in the bone morphogenetic protein receptor type 2 gene (BMPR2).

67 despite clinical and molecular similarity to bone morphogenetic protein receptor type 2 mutation-asso

68 rowth factor (TGF) beta signaling, including bone morphogenetic protein receptor type 2, activin rece

69 lular domains (ECDs) of its type I receptor [bone morphogenetic protein receptor type Ia (BMPR-Ia)-EC

70 LNGFR, HLA-DR, CD10, CD13, CD90, STRO-1, and bone morphogenetic protein receptor type IA (BMPRIA) and

71 Mutations in the gene encoding the bone morphogenetic protein receptor type II (BMPR2) are

72 erozygous mutations in the gene encoding the bone morphogenetic protein receptor type II (BMPR2) have

73 Since the landmark discovery that bone morphogenetic protein receptor type II (BMPR2) muta

74 Interferon-inducible protein 16 (IFI16), bone morphogenetic protein receptor type II (BMPRII), an

75 n: activin A receptor type IIA (ActRIIA) and bone morphogenetic protein receptor type II (BMPRII).

76 One of these genes (BMPR2), which encodes bone morphogenetic protein receptor type II, was found t

77 Loss-of-function mutations in the bone morphogenetic protein receptor type-II (BMPR-II) ar

78 lls showed cell-surface immunoreactivity for bone-morphogenetic protein receptor type 2 and nuclear i

79 t of proximal mesenchymal cells that express bone morphogenetic protein receptor, type 1B (Bmpr1b) at

80 Discriminating genes included bone morphogenetic protein receptor, type II (BMPRII).

81 duced aggregation; 2) rs11202221, in BMPR1A (bone morphogenetic protein receptor type1A), replicated